SEC Form 4 · accession 0001649325-15-000009
NephroGenex, Inc. · NRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jaikrishna Patel
Officer — Chief Medical Officer
Period of report
Aug 6, 2015
Accepted (ET)
Aug 7, 2015 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $4.12 | Aug 6, 2015 | A | 54,347 | A | Aug 6, 2016 | Aug 6, 2025 | Common Stock | 54,347 | 54,347 | D |
Explanation of responses
- F125% of the shares underlying the options will vest on April 30, 2016 and the remainder of the shares underlying the options will vest on a pro rata monthly basis for a three-year period following April 30, 2016.